Kristen Robillard, MD
Family Medicine · Hamburg, NYNPI 1508800491
Payments from drug & device makers
Across 88 payments — averaging $129.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- Kowa Research Institute, Inc.$3K
- AstraZeneca$550
- AbbVie$270
- Novo Nordisk$173
- Lilly USA, LLC$73
- plus $443 from 16 others
What the payments were for
- Consulting fees$5,00058%
- Grants$5957%
- Travel & lodging$1,02612%
- Food & beverage$1,98123%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $7,115 |
| Kowa Research Institute, Inc. | 2 | $2,765 |
| AstraZeneca | 11 | $550 |
| AbbVie | 9 | $270 |
| Novo Nordisk | 10 | $173 |
| Lilly USA, LLC | 4 | $73 |
| Amgen | 4 | $70 |
| Exact Sciences | 3 | $54 |
| Abbott | 2 | $40 |
| Seqirus USA Inc | 2 | $36 |
| Merck | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| Pfizer | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Foundation Fusion Solutions, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$242
- FARXIGA$222
- VRAYLAR$125
- BREZTRI$103
- AIRSUPRA$103
How this compares
$11,388 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 138 | $117,804 |
| OzempicSemaglutide | 67 | $107,037 |
| MounjaroTirzepatide | 69 | $88,115 |
| RybelsusSemaglutide | 43 | $69,404 |
| JardianceEmpagliflozin | 59 | $68,775 |
| EliquisApixaban | 56 | $54,313 |
| FarxigaDapagliflozin Propanediol | 45 | $40,495 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $35,133 |
| ProliaDenosumab | 20 | $34,152 |
| SynjardyEmpagliflozin/Metformin Hcl | 33 | $34,129 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $32,390 |
| XareltoRivaroxaban | 31 | $28,598 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $22,402 |
| InvokanaCanagliflozin | 19 | $21,948 |
| TrulicityDulaglutide | 15 | $14,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $173 | $176,441110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $7,115 | $148,196206 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $14 | $112,953106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $102,56484 claims |
| PfizerEliquis | $22 | $54,31356 claims |
| Johnson & JohnsonXarelto, Invokana | $13 | $50,54650 claims |
| AstraZenecaFarxiga | $550 | $40,49545 claims |
| AmgenProlia | $70 | $34,15220 claims |
| AbbVieLinzess, Synthroid | $270 | $15,88676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Hamburg
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.